Pfizer announces positive results from Phase 3 Study of Abrysvo
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
Highly effective preservation solutions ensuring the safety and protection of personal care products
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
International Business is expected to register double-digit growth in constant currency terms
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Application based on results from the TROPION-Breast01 Phase III trial
Subscribe To Our Newsletter & Stay Updated